Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer's mighty Eylea in the US – and could soon start making inroads against its rival in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results